Login
Navigate Fool.com
Will RNN beat
the market?

Rexahn Pharmaceuticals

NYSEMKT: RNN

Community Rating: 3 Stars: Appealing

0.98 0.02 (2.09%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $0.99
Previous Close $0.96
Daily Range $0.93 - $1.00
52-Week Range $0.28 - $1.85
Market Cap $173.0M
P/E Ratio -13.71
Dividend (Yield) $0.00 (0.0%)
Volume 1,966,086
Average Daily Volume 6,234,489
Current FY EPS -$0.08

How do you think RNN
will perform against the market?

Top RNN Bull/Bear Pitches

 

Louiethelooper (0)
Submitted April 20, 2010

Investors misunderstood Dr. Ahn's NYC announcement about Serdaxin results. The man used to work for the FDA and has been in scientific research all his life. He's no fool. He didn't travel all the way … More

1 Replies Reply Report this Post
 

EclecticRecluse (< 20)
Submitted April 19, 2010

Low Sales and Return on Equity

0 Replies Reply Report this Post

News & Commentary Rss Feed

This Week in Biotech: NW Bio Soars While Geron Goes Geronimo

Two early-stage study results, a rare hospital exemption approval in Germany, and a devastating full clinical hold for one biotech are among this week's top biotech stories.

Why Rexahn Pharmaceuticals Inc. Jumped Higher

Rexahn shares soar after reporting initial phase 1 results for solid tumor cancer drug supinoxin. Here's why investors may want to temper that excitement just a bit.

Rexahn Announces $5.3 Million At Market Registered Direct Offering

Rexahn Pharmaceuticals In-Licenses Novel Oligonucleotide Targeted Drug Delivery Platform from Ohio S

Rexahn Pharmaceuticals Announces Publication of Preclinical Data for Novel Anti-Cancer Compound RX-3

Rexahn Awarded Patent in Europe for Cancer Drug Archexin®

Rexahn Pharmaceuticals to Present at the 15th Annual Rodman & Renshaw Global Investment Conference o

Rexahn Pharmaceuticals Provides a Clinical Development and Financial Update

Rexahn Pharmaceuticals Announces Teva will not Exercise its Option to License RX-3117

Rexahn Pharmaceuticals Initiates Dosing in Phase I Trial of SupinoxinTM (RX-5902) a Candidate for Tr

See More RNN News...

Sector

Healthcare

Industry

Drugs

Rexahn Pharmaceuticals (RNN) Description

Rexahn Pharmaceuticals Inc. is a clinical stage biopharmaceutical company developing and seeking to deliver novel cures for cancer and disorders of the central nervous system (CNS) to patients worldwide. Website: http://www.rexahn.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks